Oncolytic viruses (OVs) are an emerging cancer therapeutic that intended to act by selectively targeting and lysing cancerous cells stimulating anti-tumour immune responses, while leaving normal mainly unaffected. Reovirus is a well-studied OV undergoing advanced clinical trials has received FDA approval in selected circumstances. However, the mechanisms governing reoviral selectivity not well ...